bioRxiv · 10.1101/2024.01.22.576650
Identification of a Binding Site for Small Molecule Inhibitors Targeting Human TRPM4
Abstract
Transient receptor potential (TRP) melastatin 4 (TRPM4) protein is a calcium-activated monovalent cation channel associated with various genetic and cardiovascular disorders. The anthranilic acid derivative NBA is a potent and specific TRPM4 inhibitor, but its binding site in TRPM4 has been unknown, although this information is crucial for drug development targeting TRPM4. We determined three cryo-EM structures of full-length human TRPM4 embedded in native lipid nanodiscs without inhibitor, bound to NBA, and a new anthranilic acid derivative, IBA. We found that the small molecules NBA and IBA were bound in a pocket formed between the S3, S4, and TRP helices and the S4-S5 linker of TRPM4. Our structural data and results from patch clamp experiments enable validation of a binding site for small molecule inhibitors, paving the way for further drug development targeting TRPM4.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ekundayo, B., Arullampalam, P., Gerber, C., Haemmerli, A.-F., Guichard, S., Boukenna, M., Ross-Kaschitza, D., Lochner, M., Rougier, J.-S., Stahlberg, H., Abriel, H., Ni, D.. 2024-01-23. Identification of a Binding Site for Small Molecule Inhibitors Targeting Human TRPM4. https://doi.org/10.1101/2024.01.22.576650
Cite the original work for its findings. Save a collection to share your selection of sources.